UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 122

Sortiert nach

Evaluating the impact of COVID‐19 on cancer declarations in Quebec, Canada

Cancer medicine (Malden, MA), 2023-03, Vol.12 (5), p.6260-6269

2023

Link zum Volltext

Verfügbarkeit prüfen

Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up

Canadian Journal of Surgery, 2014-02, Vol.57 (1), p.26-32

2014

Link zum Volltext

Verfügbarkeit prüfen

Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast Cancer

Journal of clinical oncology, 2004-09, Vol.22 (18), p.3685-3693

2004

Link zum Volltext

Verfügbarkeit prüfen

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

The lancet oncology, 2005-11, Vol.6 (11), p.886-898

2005

Link zum Volltext

Verfügbarkeit prüfen

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

The lancet oncology, 2011-04, Vol.12 (4), p.369-376

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Journal of clinical oncology, 2009-12, Vol.27 (35), p.5906-5910

2009

Link zum Volltext

Verfügbarkeit prüfen

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

Journal of clinical oncology, 2010-02, Vol.28 (6), p.960-966

2010

Link zum Volltext

Verfügbarkeit prüfen

Evaluation of the impact of interdisciplinarity in cancer care

BMC health services research, 2011-06, Vol.11 (1), p.144-144, Article 144

2011

Link zum Volltext

Verfügbarkeit prüfen

Effect of postchemotherapy nausea and vomiting on health-related quality of life

Supportive care in cancer, 1997-07, Vol.5 (4), p.307-313

1997

Link zum Volltext

Verfügbarkeit prüfen

Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation

BMJ quality & safety, 2011-03, Vol.20 (3), p.228-236

2011

Link zum Volltext

Verfügbarkeit prüfen

Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer

Journal of clinical oncology, 2004-03, Vol.22 (5), p.864-871

2004

Link zum Volltext

Verfügbarkeit prüfen

Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors

Journal of clinical oncology, 2000-12, Vol.18 (24), p.4098-4108

2000

Link zum Volltext

Verfügbarkeit prüfen

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer

Clinical lung cancer, 2003-01, Vol.4 (4), p.231-236

2003

Link zum Volltext

Verfügbarkeit prüfen

Prioritizing surgery during the COVID-19 pandemic: the Quebec guidelines

Canadian journal of surgery, 2021-02, Vol.64 (1), p.E103-E107

2021

Link zum Volltext

Verfügbarkeit prüfen

Adaptation of clinical guidelines: literature review and proposition for a framework and procedure

International journal for quality in health care, 2006-06, Vol.18 (3), p.167-176

2006

Link zum Volltext

Verfügbarkeit prüfen

Integrated oncogeriatric approach: a systematic review of the literature using concept analysis

BMJ open, 2012-01, Vol.2 (6), p.e001483

2012

Link zum Volltext

Verfügbarkeit prüfen

Adherence to adjuvantendocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up

Canadian journal of surgery, 2014-02, Vol.57 (1), p.26

2014

Link zum Volltext

Verfügbarkeit prüfen

Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer

Journal of clinical oncology, 1999-05, Vol.17 (5), p.1458-1464

1999

Link zum Volltext

Verfügbarkeit prüfen

Quality of life studies in chemotherapy-induced emesis

Oncology, 1996-01, Vol.53 Suppl 1, p.92

1996

Link zum Volltext

Verfügbarkeit prüfen

Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer

Cancer, 2005-10, Vol.104 (7), p.1343-1348

2005

Link zum Volltext

Verfügbarkeit prüfen

Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women

Cancer, 1999-03, Vol.85 (5), p.1104-1113

1999

Link zum Volltext

Verfügbarkeit prüfen

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3515-3515

2013

Link zum Volltext

Verfügbarkeit prüfen

A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer

Breast cancer research and treatment, 2004-11, Vol.88 (2), p.187-196

2004

Link zum Volltext

Verfügbarkeit prüfen

Induction treatment in first-line with chemotherapy + bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study

Journal of clinical oncology, 2013-02, Vol.31 (4_suppl), p.457-457

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 122

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(110)
Mit Volltextzugriff
(108)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Evaluating the impact of COVID‐19 on cancer declarations in Quebec, Canada

Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial

Adherence to adjuvant endocrine therapy in estrogen receptor–positive breast cancer patients with regular follow-up

Compliance With Consensus Recommendations for Systemic Therapy Is Associated With Improved Survival of Women With Node-Negative Breast Cancer

Selection of adjuvant chemotherapy for treatment of node-positive breast cancer

Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study

Phase II Multicenter Trial of Anthracycline Rechallenge With Pegylated Liposomal Doxorubicin Plus Cyclophosphamide for First-Line Therapy of Metastatic Breast Cancer Previously Treated With Adjuvant Anthracyclines

Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steady–State Serum Concentrations and Is Well Tolerated

Evaluation of the impact of interdisciplinarity in cancer care

Effect of postchemotherapy nausea and vomiting on health-related quality of life

Guideline adaptation: an approach to enhance efficiency in guideline development and improve utilisation

Activity and Safety of the Antiestrogen EM-800, the Orally Active Precursor of Acolbifene, in Tamoxifen-Resistant Breast Cancer

Phase I Dose-Finding Study of a New Taxane, RPR 109881A, Administered as a One-Hour Intravenous Infusion Days 1 and 8 to Patients With Advanced Solid Tumors

Phase I/II Trial of the Safety and Efficacy of AE-941 (Neovastat®) in the Treatment of Non–Small-Cell Lung Cancer

Prioritizing surgery during the COVID-19 pandemic: the Quebec guidelines

Adaptation of clinical guidelines: literature review and proposition for a framework and procedure

Integrated oncogeriatric approach: a systematic review of the literature using concept analysis

Adherence to adjuvantendocrine therapy in estrogen receptor-positive breast cancer patients with regular follow-up

Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer

Quality of life studies in chemotherapy-induced emesis

Investigating the correlation between hospital of primary treatment and the survival of women with breast cancer

Compliance with consensus recommendations for the treatment of early stage breast carcinoma in elderly women

Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial

A population-based study of the impact of delaying radiotherapy after conservative surgery for breast cancer

Induction treatment in first-line with chemotherapy + bevacizumab (bev) in metastatic colorectal cancer: Results from the gercor-DREAM phase III study

Suchergebnisse filtern